GoAI
Get started
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc.

CAI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$26.27

+$1.69 · +6.88%

Aug 21, 4:00 PM ET

CAI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

75

Undervalued

Momentum

29

Weakening

Sentiment

65

Bullish

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David Dean Halbert
Listed since
Jun 18, 2025
Employees
1,846

Market position

Day range

Current $26.27

52-week range

Current $26.27

Open
$24.7723
Previous close
$24.58
Volume
6.39M
1.85× average
Average volume
3.45M
Average daily volume
Market cap
7.43B USD
Beta
0.68
Market reference 1
50-day average
$18.4164
+42.64% above average
200-day average
$20.9414
+25.45% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
70.64×
P/B (TTM)
12.56×
P/S (TTM)
7.5×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
69.66%
Operating margin
15.49%
Net margin
10.62%

Financial health

Debt / equity
0.76×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends85%9%-67%-143%Gross margin, FY2020: 62.64%Gross margin, FY2022: 30.96%Gross margin, FY2023: 29.17%Gross margin, FY2024: 43.37%Gross margin, FY2025: 66.40%Operating margin, FY2020: 47.31%Operating margin, FY2022: -122.16%Operating margin, FY2023: -104.38%Operating margin, FY2024: -62.37%Operating margin, FY2025: 5.56%Net margin, FY2020: 9.43%Net margin, FY2022: -124.12%Net margin, FY2023: -111.53%Net margin, FY2024: -68.38%Net margin, FY2025: -66.25%FY2020FY2022FY2023FY2024FY2025
Gross margin FY2020 62.64%. Gross margin FY2022 30.96%. Gross margin FY2023 29.17%. Gross margin FY2024 43.37%. Gross margin FY2025 66.40%. Operating margin FY2020 47.31%. Operating margin FY2022 -122.16%. Operating margin FY2023 -104.38%. Operating margin FY2024 -62.37%. Operating margin FY2025 5.56%. Net margin FY2020 9.43%. Net margin FY2022 -124.12%. Net margin FY2023 -111.53%. Net margin FY2024 -68.38%. Net margin FY2025 -66.25%.

Income trends

Revenue

812.03M USD+96.97%

Operating income

45.11M USD+302.24M USD

Net income

−537.96M USD-90.84%
Income trends across reported periods947.03M USD407.04M USD−132.96M USD−672.96M USDRevenue, FY2020: 294.01M USDRevenue, FY2022: 258.49M USDRevenue, FY2023: 306.13M USDRevenue, FY2024: 412.26M USDRevenue, FY2025: 812.03M USDOperating income, FY2020: 139.09M USDOperating income, FY2022: −315.76M USDOperating income, FY2023: −319.55M USDOperating income, FY2024: −257.12M USDOperating income, FY2025: 45.11M USDNet income, FY2020: 27.73M USDNet income, FY2022: −320.83M USDNet income, FY2023: −341.42M USDNet income, FY2024: −281.89M USDNet income, FY2025: −537.96M USDFY2020FY2022FY2023FY2024FY2025
Revenue FY2020 294.01M USD. Revenue FY2022 258.49M USD. Revenue FY2023 306.13M USD. Revenue FY2024 412.26M USD. Revenue FY2025 812.03M USD. Operating income FY2020 139.09M USD. Operating income FY2022 −315.76M USD. Operating income FY2023 −319.55M USD. Operating income FY2024 −257.12M USD. Operating income FY2025 45.11M USD. Net income FY2020 27.73M USD. Net income FY2022 −320.83M USD. Net income FY2023 −341.42M USD. Net income FY2024 −281.89M USD. Net income FY2025 −537.96M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2020
Revenue812.03M USD412.26M USD306.13M USD258.49M USD294.01M USD
Cost of goods sold272.87M USD233.48M USD216.82M USD178.46M USD109.86M USD
Gross profit539.17M USD178.78M USD89.31M USD80.02M USD184.16M USD
Research and development45.31M USD113.92M USD116.88M USD101.27M USD—
Selling, general, and administrative392.47M USD321.86M USD291.48M USD294.51M USD27.31M USD
Operating expenses494.06M USD435.9M USD408.86M USD395.78M USD45.07M USD
Interest income16.5M USD7.12M USD11.26M USD947K USD—
Interest expense56.85M USD50.03M USD31.61M USD26.68M USD61.57M USD
Depreciation and amortization22.62M USD48.91M USD49M USD48.25M USD110.65M USD
Operating income45.11M USD−257.12M USD−319.55M USD−315.76M USD139.09M USD
Net income−537.96M USD−281.89M USD−341.42M USD−320.83M USD27.73M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+287.22%
11 comparable reports
Latest EPS result
-0
Estimate 0.01 · Miss by 139.18%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.231.880.53-0.82Q4 '21BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q4 2021, reported Nov 5, 2021: actual 2.95, estimate 0.61, surprise +383.61%, Beat. Q2 2025, reported Jun 9, 2025: actual -0.35, estimate -0.218, surprise -60.32%, Miss. Q3 2025, reported Aug 12, 2025: actual -0.54, estimate -0.21, surprise -157.14%, Miss. Q4 2025, reported Nov 5, 2025: actual 0.08, estimate -0.08, surprise +200.00%, Beat. Q1 2026, reported Feb 26, 2026: actual 0.28, estimate 0.01, surprise +2700.00%, Beat. Q2 2026, reported May 7, 2026: actual -0.002, estimate -0.02, surprise +91.00%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.002, estimate 0.006, surprise -139.18%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates309.1M231.63M154.17M76.71MQ4 '21BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q4 2021, reported Nov 5, 2021: actual 100.83M USD, estimate 90.24M USD, surprise +11.73%, Beat. Q2 2025, reported Jun 9, 2025: actual 120.91M USD, estimate 138.04M USD, surprise -12.41%, Miss. Q3 2025, reported Aug 12, 2025: actual 181.4M USD, estimate 138.04M USD, surprise +31.41%, Beat. Q4 2025, reported Nov 5, 2025: actual 216.83M USD, estimate 174.05M USD, surprise +24.58%, Beat. Q1 2026, reported Feb 26, 2026: actual 292.89M USD, estimate 209.54M USD, surprise +39.78%, Beat. Q2 2026, reported May 7, 2026: actual 216.17M USD, estimate 209.42M USD, surprise +3.23%, Beat. Q3 2026, reported Aug 5, 2026: actual 263.71M USD, estimate 238.11M USD, surprise +10.75%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 255.5M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

7 ratings
Strong buy00%
Buy686%
Hold114%
Sell00%
Strong sell00%

CAI news

seekingalpha.com

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial launch of Caris…

Read source
seekingalpha.com

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2

Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.54 per share a year ago.

Read source
marketbeat.com

Caris Life Sciences Q2 Earnings Call Highlights

Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services,…

Read source
prnewswire.com

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total…

Read source
seekingalpha.com

Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection

Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implying ~35% upside, and 23%-26% 2026 estimated revenue growth. CAI's proprietary WES/WTS/WGS technology and massive data…

Read source

CAI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CAI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
63.73M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
45.83M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
26.48M
Weight
0.06%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
22.47M
Weight
0.21%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
iShares Russell Mid-Cap Growth ETF logoiShares Russell Mid-Cap Growth ETFIWP
Market value
15.65M
Weight
0.08%
AUM
20.62B USD
Expense ratio
0.23%
Price / 1D
$143.66+0.99%
iShares Russell Mid-Cap ETF logoiShares Russell Mid-Cap ETFIWR
Market value
12.25M
Weight
0.02%
AUM
57.66B USD
Expense ratio
0.18%
Price / 1D
$113.44+0.70%
iShares Russell 1000 Growth ETF logoiShares Russell 1000 Growth ETFIWF
Market value
10.05M
Weight
0.01%
AUM
125.47B USD
Expense ratio
0.18%
Price / 1D
$122.39+0.47%
iShares Genomics Immunology and Healthcare ETF logoiShares Genomics Immunology and Healthcare ETFIDNA
Market value
6.93M
Weight
2.82%
AUM
250.38M USD
Expense ratio
0.47%
Price / 1D
$40.08+2.01%

Continue in GoAI

Research CAI

research.disclaimer